A notable candidate is formononetin, an isoflavonoid from Astragalus membranaceus and Astragalus mongholicus, with anti-angiogenic and anti-cancer activities that suppresses FGF2-triggered activation of FGFR2 and Akt signaling, in both breast cancer cells and a xenograft model of breast cancer, and enhances the effect of the VEGFR2 inhibitor, sunitinib, on tumor growth inhibition (Wu et al., 2015). This evidence concerns the gene FGF2 and breast cancer.